Program: Education Program
Session: Adult ALL Advancements: Optimizing Cure in 2024
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Session: Adult ALL Advancements: Optimizing Cure in 2024
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024, 2:45 PM-4:00 PM
Disclosures: Luskin: AbbVie: Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria; KITE: Honoraria; Jazz: Honoraria.
Previous Presentation
|
Next Presentation >>